文献速递妇科

基于HPV基因型的纵向甲基化分析用于CIN2病变风险分层

Longitudinal methylation analysis for risk stratification of CIN2 lesions by HPV genotype
RSS 订阅 · Acta Obstetricia et Gynecologica Scandinavica · 2026-11-10

该研究纳入122例18–30岁组织学确诊的CIN2女性,在芬兰赫尔辛基大学医院接受主动监测,每6个月随访至24个月。基线S5分类器显著预测进展/持续(OR 1.15,95%CI 1.05–1.25),排除HPV16/18后呈临界预测关联(OR 1.19,95%CI 1.00–1.41)。S5甲基化水平在进展者中持续升高,可提前至组织学诊断前18个月预测进展/持续。

要点

  • 基线S5分类器显著预测未治疗CIN2的进展/持续,OR 1.15(95%CI 1.05–1.25)。
  • 排除HPV16/18后S5分类器呈临界预测关联(OR 1.19,95%CI 1.00–1.41),细胞学和HPV分型未显示预测作用。
  • 进展者S5甲基化水平在24个月内持续升高,可提前至组织学诊断前18个月预测进展。

核心结论

  • 在该主动监测队列中,S5分类器有潜力作为未治疗CIN2进展的预后分诊生物标志物,包括非HPV16/18型病例。
  • 探索性发现提示甲基化水平升高可能先于组织学进展达18个月。
  • 随着HPV16/18流行率下降,宿主-病毒甲基化面板可能较标准分诊提供更好的风险分层,但需在接种疫苗人群中开展更大规模前瞻性研究以确认这些发现并确立临床效用。

研究设计与样本

  • 研究纳入122例年龄18–30岁、组织学确诊CIN2的女性,来自芬兰赫尔辛基大学医院的一项主动监测试验(ISRCTN91953024)。
  • 患者每6个月接受细胞学、HPV基因分型和阴道镜检查,随访至24个月。
  • 采用焦磷酸测序检测S5甲基化水平,比较消退至正常组织学女性(n=89)与进展至CIN3+(n=22,含1例微浸润癌)或持续CIN2(n=11)女性。
  • 分析按基线HPV基因型分层。

主要发现

  • 基线S5分类器显著预测进展/持续,OR 1.15(95%CI 1.05–1.25)。
  • 排除HPV16/18后,S5分类器显示相似的临界预测关联(OR 1.19;95%CI 1.00–1.41),而细胞学和HPV基因分型未显示预测作用。
  • 纵向分析显示进展者S5甲基化水平在整个24个月期间持续升高,显著预测进展/持续可提前至组织学诊断进展前18个月。

临床怎么用

  • 原文结论指出S5分类器的预测提前时间可能支持风险分层主动监测,有助于减少过度治疗及相关产科并发症,同时确保进展性疾病得到及时管理。
  • 作者认为随着HPV16/18流行率下降,宿主-病毒甲基化面板可能较标准分诊提供更好的风险分层。
  • 作者指出需在接种疫苗人群中开展更大规模前瞻性研究以确认这些发现并确立临床效用。

局限性

  • 原文指出这些为探索性发现。
  • 原文指出需在接种疫苗人群中开展更大规模前瞻性研究以确认这些发现并确立临床效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The S5 classifier demonstrates promising utility for predicting CIN2 progression, including in non-HPV16/18 infections. Its predictive lead time may support risk-stratified active surveillance, helping reduce overtreatment and associated obstetric complications while ensuring timely management of progressive disease. Abstract Introduction There is an urgent need for biomarkers that can distinguish regressive from progressive cervical intraepithelial neoplasia (CIN) lesions to improve risk stratification in cervical cancer screening programs and avoid overtreatment. We aimed to evaluate the longitudinal performance of the S5 methylation classifier in predicting the clinical trajectory of untreated CIN grade 2 (CIN2) across different HPV genotype groups. Material and Methods This study included 122 women (aged 18–30) with histologically confirmed CIN2 enrolled in an active surveillance trial at Helsinki University Hospital, Finland (ISRCTN91953024). Patients were monitored every 6 months for up to 24 months with cytology, HPV genotyping, and colposcopy. S5 methylation levels (pyrosequencing) were compared between women who regressed to normal histology (n = 89) and those who progressed to CIN3+ (n = 22, including one microinvasive cancer) or had persistent CIN2 (n = 11). Analysis was stratified based on baseline HPV genotypes. Results The baseline S5 classifier significantly predicted progression/persistence with an odds ratio (OR) of 1.15 (95%CI 1.05–1.25). When excluding HPV16/18, the S5 classifier demonstrated a similar, borderline predictive association (OR 1.19; 95%CI 1.00–1.41), whereas cytology and HPV genotyping did not. Longitudinal analysis showed that S5 methylation levels in progressors remained elevated throughout the 24-month period, significantly predicting progression/persistence up to 18 months prior to histological diagnosis of progression. Conclusions In this active surveillance cohort, the S5 classifier showed potential as a prognostic triage biomarker for identifying progression in untreated CIN2, including cases with non-HPV16/18 types. Our exploratory findings suggest that elevated methylation levels may precede histological progression by up to 18 months. As HPV16/18 prevalence declines, host-viral methylation panels may offer improved risk stratification compared to standard triage, though larger prospective studies in vaccinated populations are needed to confirm these findings and establish clinical utility.

来源:Acta Obstetricia et Gynecologica Scandinavica,查看原文。版权归原作者所有。

引用

  1. Acta Obstetricia et Gynecologica Scandinavica:Longitudinal methylation analysis for risk stratification of CIN2 lesions by HPV genotype

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。